Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - PHASERX, INC. | v452454_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - PHASERX, INC. | v452454_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 8, 2016
PhaseRx, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-37772 | 20-4690620 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 410 W. Harrison Street, Suite 300 Seattle, Washington |
98119 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, includig area code: (206) 805-6300
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
PhaseRx, Inc. (the “Company”) intends, from time to time, to present and/or distribute to the investment community and utilize at various industry and other conferences a slide presentation of non-human primate safety study data, which is attached hereto as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing.
Item 8.01. Other Events.
On November 8, 2016, the Company issued a press release announcing positive results from the Company’s single escalating dose response study in non-human primates. A copy of this press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Slide Presentation of Non-Human Primate Safety Study Data of PhaseRx, Inc. dated November 8, 2016 | |
| 99.2 | Press release, dated November 8, 2016 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PhaseRx, Inc. | ||
| Date: November 8, 2016 | By: | /s/ Robert W. Overell |
| Robert W. Overell, Ph.D. | ||
| Chief Executive Officer | ||